국가: 뉴질랜드
언어: 영어
출처: Medsafe (Medicines Safety Authority)
Ranitidine hydrochloride 16.8 mg/mL equivalent to Ranitidine 15 mg/mL;
GlaxoSmithKline NZ Limited
Ranitidine hydrochloride 16.8 mg/mL (=Ranitidine 15 mg/mL)
150mg/10mL
Syrup
Active: Ranitidine hydrochloride 16.8 mg/mL equivalent to Ranitidine 15 mg/mL Excipient: Butyl hydroxybenzoate Dibasic sodium phosphate Ethanol Hypromellose Mint flavour 17.42.3632 Monobasic potassium phosphate Propyl hydroxybenzoate Saccharin sodium Sodium chloride Sorbitol Water
Bottle, glass, 300 mL
Prescription
Prescription
Glaxo Wellcome Manufacturing Pte Ltd
-The treatment of duodenal ulcer, and benign gastric ulcer, including that associated with non-steroidal anti- inflammatory agents. - The prevention of non-steroidal anti-inflammatory agent (including aspirin) associated duodenal ulcers in patients with a history of duodenal ulceration proven by endoscopy. - The treatment of post-operative ulcer - The treatment of oesophageal reflux disease - Symptom relief in gastro-oesophageal reflux disease - The treatment of Zollinger-Ellison syndrome - The treatment of chronic episodic dyspepsia, characterised by pain (epigastric or retrosternal) which is related to meals or disturbs sleep but not associated with the above conditions. ZANTAC Syrup is also indicated for the following conditions where reduction of gastric secretion and acid output is desirable: - The prophylaxis of upper gastrointestinal haemorrhage from stress ulceration in seriously ill patients. - The prophylaxis of recurrent haemorrhage in patients with bleeding peptic ulcers. - Before general anaesthesia in patients considered to be at risk of acid aspiration (Mendelson's syndrome), particularly obstetric patients during labour.
Package - Contents - Shelf Life: Bottle, glass, - 300 mL - 24 months from date of manufacture stored at or below 25°C
1987-08-20
1 ZANTAC ® SYRUP RANITIDINE HYDROCHLORIDE, 150MG/10ML SYRUP CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? Please read this leaflet carefully before you start taking Zantac syrup. This leaflet does not have all information available about your medicine. If you have any questions about your medicine, you should ask your doctor or pharmacist. All medicines have some risks. Your doctor has weighed the risks of you taking Zantac syrup against the benefits he/she expects it will have for you. If there is anything you do not understand, ask your doctor or pharmacist. If you want more information, ask your doctor or pharmacist. WHAT ZANTAC IS USED FOR The medicine in your Zantac syrup is called ranitidine (as hydrochloride). This belongs to a group of medicines called H 2 - antagonists. Zantac is mostly used to: relieve and treat the symptoms of reflux oesophagitis (also known as reflux) treat stomach and duodenal ulcer disease (also known as peptic ulcer), including when they are caused by taking anti- inflammatory tablets. stop these ulcers from coming back treat chronic dyspepsia (indigestion) treat duodenal ulcers associated with Helicobacter _pylori _ infection, in combination with amoxicillin (antibiotic) and metronidazole (antibacterial agent) These problems are caused, in part, by too much acid in the stomach. This can lead to pain such as heartburn. Zantac works by reducing the amount of acid in the stomach. This reduces the pain and also allows the ulcer and reflux to heal. Zantac is also used to treat: Zollinger-Ellison disease – where the stomach produces very large amounts of acid, much more than in ulcers and reflux dise 전체 문서 읽기
_The medicine is not currently marketed in New Zealand _ 1 NEW ZEALAND DATA SHEET ZANTAC ® SYRUP _RANITIDINE HYDROCHLORIDE SYRUP _ _ _ QUALITATIVE AND QUANTITATIVE COMPOSITION ZANTAC Syrup: Each 10mL contains ranitidine 150mg (as the hydrochloride). PHARMACEUTICAL FORM Syrup. CLINICAL PARTICULARS _THERAPEUTIC INDICATIONS _ ZANTAC Syrup is indicated for: - the treatment of duodenal ulcer, and benign gastric ulcer, including that associated with non-steroidal anti- inflammatory agents. - the prevention of non-steroidal anti-inflammatory agent (including aspirin) associated duodenal ulcers in patients with a history of duodenal ulceration proven by endoscopy. - the treatment of post-operative ulcer - the treatment of oesophageal reflux disease - symptom relief in gastro-oesophageal reflux disease - the treatment of Zollinger-Ellison syndrome - the treatment of chronic episodic dyspepsia, characterised by pain (epigastric or retrosternal) which is related to meals or disturbs sleep but not associated with the above conditions. ZANTAC Syrup is also indicated for the following conditions where reduction of gastric secretion and acid output is desirable: - the prophylaxis of upper gastrointestinal haemorrhage from stress ulceration in seriously ill patients. _The medicine is not currently marketed in New Zealand _ 2 - the prophylaxis of recurrent haemorrhage in patients with bleeding peptic ulcers. - before general anaesthesia in patients considered to be at risk of acid aspiration (Mendelson's syndrome), particularly obstetric patients during labour. For appropriate cases ZANTAC Injection is also available (see ZANTAC Injection Data Sheet). _POSOLOGY AND METHOD OF ADMINISTRATION _ Zantac Syrup contains approximately 7.5% w/v ethanol (alcohol), i.e. up to 405 mg per 5 mL spoonful (approximately a teaspoonful) which is equivalent to about 11 mL of beer or 5 mL of wine. ADULTS Duodenal Ulcer and Benign Ga 전체 문서 읽기